RD&C BRINGS HIGH QUALITY AND CUSTOMISED EXPERTISE TO THE LIFE SCIENCE COMMUNITY

RD&C combines in depth scientific knowledge of various research disciplines to coordinate and guide innovative concepts for new drug candidates. Regulatory compliant drug development documentation and expert dossiers are provided on sound scientific and regulatory experience.

RD&C permanently monitors trends and new developments on the pharmaceutical market. The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more interest than those that simply shift the bottlenecks and necessitate new compromises in the discovery and development process.

 

Based on urgent medical needs and the (in-)availability of satisfying treatment options at acceptable side-effects, RD&C has developed research proposals aiming at the improvement and modification of existing drugs.

  1. Co-crystals of sartanes for improved bioavailability and efficacy
  2. Co-crystals of ACE (angiotensin-converting-enzyme) inhibitors for improved bioavailability and efficacy
  3. Co-crystals of statins for improved bioavailability and efficacy
  4. Co-crystals of NSAIDs and/or gabapentinoids with improved skin permeation/alternative topical application forms (gel, cream)
  5. Co-crystals of drugs with improved skin permeation for innovative application forms (patch)
  6. Co-crystals for improved blood-brain-barrier permeation to improve bioavailability and efficacy of Alzheimer drugs
  7. Co-crystal combinations for innovative and improved Alzheimer therapy
  8. Co-crystals of bisphosphonates for improved bioavailability and efficacy for treatment of osteoporosis
  9. Co-crystals of bisphosphonates for improved bioavailability and efficacy for treatment of osteoporosis in a combined dosage form with statins
  10. 4-Phenylbutyric acid co-crystals and prodrugs with improved pharmacokinetic and pharmacodynamic properties for treatment of genetic disorders and cancer
  11. Co-crystals of ACE (angiotensin-converting-enzyme) inhibitors, angiotensin II receptor antagonists, and HMG-CoA reductase inhibitors and selected drug combinations for improved bioavailability and efficacy
  12. Co-crystals of neutraceuticals: enhanced bioavailability of polyphenols as chemoprevention agents

RD&C seeks for partners to translate these concepts into reality. Please contact us if you are interested in discussing these proposals!